Targeted Therapy — When You Have Liver Disease or Cirrhosis

Possibly, yes. Cirrhosis covers a wide range of severity, and many people with mild or well-compensated cirrhosis do receive targeted therapy with dose adjustments and close monitoring. The decision depends on how well your liver is functioning now — not simply on the diagnosis of cirrhosis. Your oncologist will use blood tests and clinical assessment to judge whether your liver can safely handle a specific drug at an adjusted dose. Some drugs are more suitable than others in this situation, and your team will factor that in when choosing a regimen.

Child-Pugh is a clinical scoring system that grades liver function from A, which is mild impairment, to C, which is severe. It combines blood test results with clinical signs to describe how well the liver is compensating for the damage it has sustained. Most clinical trials of targeted therapy drugs enrolled people with Child-Pugh A liver function, so the available dosing guidance is most reliable for that group. For Child-Pugh B or C, there is less data, and oncologists must use more caution and judgment. Knowing your score tells your team which part of the available guidance applies to you.

It may, and that is one of the central reasons monitoring is so close. Some targeted drugs can cause liver inflammation as a side effect — a reaction that occurs in a proportion of patients regardless of pre-existing liver disease. When your liver is already under pressure, your team will track your liver blood tests more frequently than they would for someone without liver disease. The aim is to catch any worsening early, before it becomes serious, and to adjust or pause treatment if needed. It is a manageable risk, not an inevitable outcome.

Contact your oncology team the same day if you notice yellowing of your skin or the whites of your eyes, dark urine, very pale stools, new pain or tenderness in your upper abdomen, unusual fatigue that is clearly worse than your baseline, or swelling of your ankles or abdomen that was not there before. These can be signs of liver stress that your team needs to assess before your next scheduled appointment. Do not wait for your next blood test if the symptom is new and noticeable.

You should discuss this directly with your oncologist, but for most people with liver disease on targeted therapy the answer is yes. Alcohol is processed by the liver using some of the same pathways as many targeted therapy drugs, and it adds further stress to a liver already working under pressure. Even if you drink only occasionally, tell your team how much so they have an accurate picture. They may ask you to stop entirely, or advise on what is safe given your specific drug and current liver function.

Paracetamol is processed by the liver, and the level that is safe depends on your liver function and the specific targeted therapy you are taking. It is not safe to assume the standard over-the-counter dose applies to your situation. Ask your oncologist or pharmacist before taking it — or any other pain relief — so they can advise based on your current liver function tests and your drug regimen. This applies even to medicines you have taken safely for years, because your liver's capacity may have changed.

Not necessarily. A dose adjustment for liver impairment is calculated to give your body a similar effective drug exposure to the standard dose — not a lower one. Because the drug clears more slowly from your system, a lower starting dose is intended to reach a comparable level rather than a reduced one. Your team will monitor both your liver tests and your response to treatment. If the disease is not responding, they have the option to reassess the dose. Starting lower is a safety measure, not a concession on effectiveness.

Yes, and this matters more than most people realise. Hepatitis B can persist in the liver in an inactive form even after treatment, and certain systemic therapies — including some targeted agents — can reactivate it. Reactivation can cause serious liver damage and can happen without early warning symptoms. NCCN guidance recommends hepatitis B screening before starting many systemic cancer treatments. If reactivation risk is identified, preventive antiviral treatment can be given alongside your cancer treatment to reduce that risk. Tell your oncologist and bring any records you have of your previous hepatitis B treatment.